Seaport Therapeutics

Seaport Therapeutics is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts. The company employs 41 individuals and focuses on developing novel neuropsychiatric medications. Seaport Therapeutics specializes in advancing clinically validated mechanisms for treating neurological and psychiatric disorders. Their pipeline of therapeutic candidates utilizes the proprietary Glyph technology platform, designed to enhance oral bioavailability, circumvent first-pass metabolism, and minimize side effects like hepatotoxicity. The Glyph platform allows Seaport Therapeutics to develop first and best-in-class medications for areas of high unmet patient need. The company is led by a team with extensive experience in inventing and developing neuropsychiatric medicines, including KarXT. They are also guided by a network of distinguished scientists, clinicians, and key opinion leaders. For more information about Seaport Therapeutics and their innovative approaches to neuropsychiatric treatment, visit their website at seaporttx.com.